General physicians' perspectives on SGLT2 inhibitors for heart failure

• Published in: Internal medicine journal Vol. 54; no. 9; pp. 1483 - 1489
• Main Authors: Teng, Lung E., Lammoza, Noor, Aung, Ar K., Thayaparan, Archana, Vasudevan, Swetha, Edwards, Gail, Hormiz, Maria, Gibbs, Harry, Hopper, Ingrid
• Format: Journal Article
• Language: English
• Published: Melbourne John Wiley & Sons Australia, Ltd 01.09.2024; Wiley Subscription Services, Inc
• Subjects: barriers to prescription; Congestive heart failure; Diabetes mellitus; Ejection fraction; Familiarity; general physician; Heart failure; Ketoacidosis; Patients; Questionnaires; SGLT2 inhibitors; Side effects; Sodium-glucose cotransporter; therapeutic inertia; New Zealand; Australia
• ISSN: 1444-0903; 1445-5994; 1445-5994
• DOI: 10.1111/imj.16440

Background Sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) are novel agents for heart failure (HF) and are now recommended in guidelines. Understanding general physicians' perspectives can help to optimise utilisation of this new medication. Aim To understand the clinical concerns and barriers from general physicians about prescribing SGLT2is in a general medicine cohort. Methods A questionnaire exploring clinicians' experience, comfort level and barriers to prescribing SGLT2is in patients with HF, incorporating two clinical scenarios, was disseminated to Internal Medicine Society of Australia and New Zealand members over a 2‐month period. Results Ninety‐eight participants responded to the questionnaire (10.8% response rate). Most respondents (66.3%) were senior medical staff. Most participants worked in metropolitan settings (64.3%) and in public hospital settings (83.7%). For HF with reduced ejection fraction, 23.5% of participants reported prescribing SGLT2is frequently (defined as prescribing SGLT2is frequently over 75% of occasions). For HF with preserved ejection fraction, 57.1% of participants reported prescribing SGLT2is less than 25% of the time. Almost half of the participants (44%) expressed a high level of familiarity with therapeutic knowledge of SGLT2is, while 47% indicated high familiarity with potential side effects. Patient complexity, cost of medications and discontinuity of care were identified as important barriers. Euglycemic diabetic ketoacidosis was the side effect that caused the most hesitancy to prescribe SGLT2is in 48% of the respondents. Conclusion General physicians in Australia and Aotearoa New Zealand are familiar with the therapeutic knowledge and side effects of SGLT2is. Patient complexity, medication cost and discontinuity of care were significant barriers to the use of SGLT2is for HF among general physicians.